^
Association details:
Biomarker:TMB-L
Cancer:Malignant Pleural Mesothelioma
Drug Class:PD-L1 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes

Published date:
11/03/2020
Excerpt:
Median PFS with immunotherapy was poor with at 1.5 months (SD ±0.4). Overall PDL1 expression and TMB is low in patients with MPM resulting in limited benefit from single agent PD-1/PD-L1 agent.
DOI:
10.1016/j.ctarc.2020.100232